ESSA Pharma Inc. Common Stock
EPIX
EPIX: ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.
moreShow EPIX Financials
Recent trades of EPIX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by EPIX's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof Dec. 06, 2022
-
Patent Title: Androgen receptor modulators and methods for their use Nov. 01, 2022
-
Patent Title: Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof Jun. 14, 2022
-
Patent Title: Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof Feb. 08, 2022
-
Patent Title: Androgen receptor modulators and methods for their use Jul. 13, 2021
Federal grants, loans, and purchases
Followers on EPIX's company Twitter account
Number of mentions of EPIX in WallStreetBets Daily Discussion
Recent insights relating to EPIX
Recent picks made for EPIX stock on CNBC
ETFs with the largest estimated holdings in EPIX
Flights by private jets registered to EPIX